Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04150965
Title Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Multiple Myeloma Research Consortium
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.